Mantle Cell Lymphoma

For a mature CD5-positive B-cell neoplasm, obtain tissue morphology, B-cell immunophenotyping, cyclin D1 immunohistochemistry, and CCND1 rearrangement testing by FISH when needed. The defining lesion is t(11;14)(q13;q32), juxtaposing CCND1 with the immunoglobulin heavy-chain locus and producing cyclin D1 overexpression. PubMed+3PubMedSOX11 expression is highly specific for mantle cell lymphoma and identifies the cyclin D1-negative subtypePubMedMantle Cell Lymphoma - StatPearls - NCBI BookshelfPubMedMantle cell lymphoma - PMC - NIHPubMedThe pathologic diagnosis of mantle cell lymphoma

Use SOX11 staining to support conventional MCL when cyclin D1 is negative or technically equivocal. SOX11 is positive in more than 90% of MCL, including cyclin D1-negative and blastoid cases; rare cyclin D1-negative tumors may instead show high cyclin D2 or cyclin D3 expression. PubMed+2PubMedCyclin D1 + large B-cell lymphoma with altered CCND1 and BCL-6 rearrangements: a diagnostic challenge - PMCPubMedSOX11 expression is highly specific for mantle cell lymphoma and identifies the cyclin D1-negative subtypePubMedMantle Cell Lymphoma - StatPearls - NCBI Bookshelf

Review morphology and genetics with a hematopathologist when a cyclin D1-positive large B-cell process is encountered. Most DLBCL lacks CCND1/IGH rearrangement, cyclin D1, and SOX11, but rare DLBCL can express cyclin D1 without t(11;14) or SOX11 and can be mistaken for blastoid MCL. PubMedPubMedCyclin D1 + large B-cell lymphoma with altered CCND1 and BCL-6 rearrangements: a diagnostic challenge - PMC

At diagnosis, document measurable disease and establish a baseline for treatment response using the Lugano framework; clinical-trial criteria define measurable lymphoma as a lesion with longest diameter at least 1.5 cm, or bone marrow involvement detected by flow cytometry. clinicaltrials+1clinicaltrialsStudy Details | NCT07259070 | Multicenter, Single-Arm Exploratory Phase I Clinical Study (Assessment of Safety and Efficacy) of Fully Human BAFF-R Chimeric Antigen Receptor T-Cell Injection in Relapsed/Refractory BAFF-R-Positive B-Cell Lymphoma | ClinicalTrials.govclinicaltrialsStudy Details | NCT04767308 | Safety and Efficacy of CT125A Cells for Treatment of Relapsed/Refractory CD5+ Hematopoietic Malignancies | ClinicalTrials.gov Obtain marrow assessment when marrow involvement will affect staging, response assessment, or trial eligibility.

Treatment intensity should follow symptomatic burden, disease extent, response potential, and transplant fitness. For symptomatic advanced MCL, first-line therapy is chemotherapy combined with rituximab; the choice of intensity should account for patient fitness. nice org uknice org ukRecommendations | Non-Hodgkin lymphoma: diagnosis and management | Guidance | NICE

A patient with clinical instability from bulky disease, threatened end-organ function, cytopenias attributable to marrow infiltration, or rapidly progressive disease should proceed directly to hematology-oncology-directed treatment planning after diagnostic tissue is secured. Before cytotoxic therapy, define the intended pathway: lower-intensity chemoimmunotherapy, cytarabine-containing induction with planned high-dose consolidation, or a clinical trial.

For fit patients with advanced MCL, cytarabine-containing immunochemotherapy is a recommended consideration. If induction produces at least a partial response and the patient remains fit, high-dose chemotherapy followed by autologous stem-cell transplantation is a consolidation option. nice org uknice org ukRecommendations | Non-Hodgkin lymphoma: diagnosis and management | Guidance | NICE This pathway requires early transplant assessment during induction, rather than referral only after relapse.

For patients not fit for high-dose chemotherapy, use rituximab-containing chemotherapy selected for tolerability and disease control. Bendamustine plus rituximab is among the most commonly used first-line MCL regimens. NEJMNEJMIbrutinib plus Bendamustine and Rituximab in Untreated ... In this population, maintenance rituximab every 2 months until progression may be considered after a response to R-CHOP-based immunochemotherapy. nice org uknice org ukRecommendations | Non-Hodgkin lymphoma: diagnosis and management | Guidance | NICE

For patients in remission after cytarabine-based induction and high-dose chemotherapy, maintenance rituximab every 2 months for 3 years may be considered. nice org uknice org ukRecommendations | Non-Hodgkin lymphoma: diagnosis and management | Guidance | NICE Discuss the maintenance plan before consolidation, because the intended induction and consolidation pathway determines the applicable maintenance approach.

At first relapse after one prior treatment line, BTK inhibition is a central treatment branch; NICE identifies zanubrutinib and ibrutinib as options for adults with relapsed or refractory MCL after one line of therapy. nice org uknice org ukRecommendations | Non-Hodgkin lymphoma: diagnosis and management | Guidance | NICE Record whether a prior BTK inhibitor was covalent, whether progression occurred on treatment, and whether discontinuation was driven by intolerance, because these distinctions govern the relevance of noncovalent BTK inhibition and cellular therapy.

For MCL that has progressed after a covalent BTK inhibitor, pirtobrutinib is a noncovalent BTK inhibitor with FDA approval for relapsed or refractory MCL after at least two prior lines of therapy, including a covalent BTK inhibitor. NEJMNEJMPirtobrutinib after a Covalent BTK Inhibitor in Chronic ... This indication should not be extrapolated to BTK inhibitor-naive disease.

Refer early for cellular therapy assessment in patients with multiply relapsed disease, particularly after prior chemotherapy, anti-CD20 therapy, and BTK inhibitor exposure. Trial and product-development populations for CAR T-cell approaches have commonly required prior anthracycline- or bendamustine-containing chemotherapy, anti-CD20 therapy, and BTK inhibitor therapy. Oxford Academic+1Oxford AcademicONCO 25:S1clinicaltrialsStudy Details | NCT04767308 | Safety and Efficacy of CT125A Cells for Treatment of Relapsed/Refractory CD5+ Hematopoietic Malignancies | ClinicalTrials.gov Use a current disease assessment to determine whether there is measurable disease and whether bridging treatment is required while cellular therapy is organized.

Apply Lugano-based response assessment after induction and at suspected progression; measurable lesions are defined in trial settings as at least 1.5 cm in longest diameter, with marrow involvement assessable by flow cytometry. clinicaltrials+1clinicaltrialsStudy Details | NCT07259070 | Multicenter, Single-Arm Exploratory Phase I Clinical Study (Assessment of Safety and Efficacy) of Fully Human BAFF-R Chimeric Antigen Receptor T-Cell Injection in Relapsed/Refractory BAFF-R-Positive B-Cell Lymphoma | ClinicalTrials.govclinicaltrialsStudy Details | NCT04767308 | Safety and Efficacy of CT125A Cells for Treatment of Relapsed/Refractory CD5+ Hematopoietic Malignancies | ClinicalTrials.gov For transplant planning, distinguish complete response from partial response, but recognize that at least partial response establishes chemosensitivity for consolidation decisions. nice org uknice org ukRecommendations | Non-Hodgkin lymphoma: diagnosis and management | Guidance | NICE

After autologous transplantation, molecular relapse has been studied as a setting for pre-emptive rituximab, but this should be directed within an experienced MCL program rather than substituted for standard clinical and radiographic assessment. nice org uknice org ukNon-Hodgkin's lymphoma: diagnosis and management In patients with recurrent disease, reassess both histology and the complete exposure sequence before selecting another line.

A new aggressive clinical course or large-cell morphology should prompt renewed consideration of blastoid/pleomorphic MCL versus DLBCL. The distinction requires correlation of morphology, cyclin D1, SOX11, and CCND1/IGH rearrangement status because rare cyclin D1-positive DLBCL can mimic MCL. PubMedPubMedCyclin D1 + large B-cell lymphoma with altered CCND1 and BCL-6 rearrangements: a diagnostic challenge - PMC